Novo Nordisk A/S (NVO) est une société cotée en bourse dans le Santé secteur, opérant dans le Drug Manufacturers - General secteur d'activité. Le siège social de l'entreprise est situé à Bagsvaerd, Denmark. Le PDG actuel est Maziar Mike Doustdar.
NVO a date d'introduction en bourse 1981-04-30, 77,406 employés à temps plein, cotée sur le New York Stock Exchange, une capitalisation boursière de $174.74B.
Novo Nordisk A/S is a Danish pharmaceutical company founded in 1923 that researches, develops, manufactures, and distributes medications globally across Europe, the Middle East, Africa, China, and North America. The company operates through two primary segments: Diabetes and Obesity Care, which offers treatments for diabetes, obesity, and cardiovascular conditions, and Rare Disease, which focuses on rare blood disorders, rare endocrine disorders, and hormone replacement therapy. Beyond pharmaceutical products, Novo Nordisk provides delivery devices such as insulin pens and growth hormone pens, as well as digital health solutions including smart insulin pens and dose guidance applications. The company has established strategic collaborations with UNICEF on childhood obesity initiatives and with Valo Health to develop cardiometabolic therapies.
